Ultragenyx Pharmaceutical (RARE) Change in Receivables (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Change in Receivables data on file, last reported at -$19.0 million in Q1 2026.

• Quarterly Change in Receivables fell 90.0% year-over-year to -$19.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.0 million (up 2522.91% YoY) and the FY2025 annual result came in at $31.0 million, down 8.82% from the prior year.
• Change in Receivables declined to -$19.0 million in Q1 2026 per RARE's latest filing, from $33.8 million in the prior quarter.
• Across five years, Change in Receivables topped out at $33.8 million in Q4 2025 and bottomed at -$19.0 million in Q1 2026.
• The 5-year median for Change in Receivables is $2.5 million (2023), against an average of $4.8 million.
• The widest annual swing landed in 2022, when Change in Receivables tumbled 955.56%; it then jumped 7700.0% in 2023.
• Tracing RARE's Change in Receivables over 5 years: stood at $9.1 million in 2022, then tumbled by 108.69% to -$790000.0 in 2023, then soared by 2763.54% to $21.0 million in 2024, then surged by 60.79% to $33.8 million in 2025, then slumped by 156.16% to -$19.0 million in 2026.
• Per Business Quant, the three latest RARE Change in Receivables figures stand at -$19.0 million (Q1 2026), $33.8 million (Q4 2025), and -$5.4 million (Q3 2025).

Peer Comparison